S

Seagen Inc
F:SGT

Watchlist Manager
Seagen Inc
F:SGT
Watchlist
Price: 208.6 EUR Market Closed
Market Cap: 39.4B EUR

Seagen Inc
Investor Relations

Seagen Inc., nestled in the vibrant Pacific Northwest, has carved out a formidable niche in the biotech arena with its relentless focus on oncology advancements. Born in 1997 as Seattle Genetics, this company has developed a reputation for its pioneering work in antibody-drug conjugates (ADCs). These innovative therapies are designed to deliver potent anti-cancer agents directly to tumor cells, minimizing damage to healthy tissues. Its flagship product, Adcetris, targets various Hodgkin’s lymphomas and has been instrumental in redefining treatment paradigms. This high-caliber development is not just a product of cutting-edge science, but of Seagen's strategic approach to partnerships and collaborations with other pharmaceutical giants, amplifying its research and market reach.

Revenue for Seagen doesn't merely stem from its internal product pipeline; it also thrives on strategic alliances and licensing agreements. By engaging in collaborations with leading firms like Pfizer and Takeda, Seagen extends its influence beyond its direct sales, earning substantial sums from milestone payments and royalties as partners bring drugs to market. Furthermore, its business model is deeply entwined with a global vision, where navigating regulatory landscapes across different countries not only expands its market share but also its scientific influence. Seagen’s business strategy is a testament to how innovation in drug delivery mechanisms and thoughtful alliances can coalesce into a formidable presence in the biopharmaceutical industry, fueling both growth and a greater mission in the fight against cancer.

Show more
Loading

Earnings Calls

2022 Q4
Feb 15, 2023
Show Transcript
Previous
Next
Seagen Reports Strong Growth with Future Potential in Oncology Market
2022 Q4
Feb 15, 2023

Seagen concluded 2022 with total revenues of $1.96 billion, a year-over-year increase of 25%. Product sales reached $1.7 billion, driven by ADCETRIS and PADCEV. The company anticipates 2023 revenues between $2.14 billion and $2.24 billion, reflecting 9% to 14% growth. They project product sales of $1.925 billion to $2.0 billion, up 13% to 17%. Notable regulatory milestones include PADCEV’s potential first-line approval expected on April 21, 2023, and continued efforts to expand the commercial footprint of their portfolio. Seagen remains focused on investing in promising pipeline candidates to sustain long-term growth.

Management

Mr. Todd E. Simpson
Chief Financial Officer

Todd E. Simpson is the Chief Financial Officer (CFO) of Seagen Inc., a biotechnology company that focuses on developing and commercializing innovative cancer therapies. In his role as CFO, Simpson is responsible for overseeing the company's financial operations, including financial planning and analysis, accounting, tax, treasury, and investor relations. Before joining Seagen, Todd Simpson had a distinguished career with significant experience in the finance sector, particularly within the biopharmaceutical industry. He has a proven track record of leading financial operations and strategies that support company growth and long-term value creation. Simpson's expertise is not solely limited to finance; he has played critical roles in business development initiatives, capital market strategies, and financial risk management. His leadership style is often noted for being strategic and collaborative, focusing on driving performance and operational efficiency. His professional background and accomplishments at Seagen are a testament to his ability to align financial objectives with strategic company goals, which has been critical in supporting the company’s mission to make a meaningful difference in cancer care through innovative treatments.

Ms. Jean I. Liu J.D., M.S.
Chief Legal Officer

Jean I. Liu, J.D., M.S., is a distinguished executive known for her role as an officer at Seagen Inc., a biotechnology company focused on developing and commercializing innovative cancer treatments. Ms. Liu has an extensive background in both legal and corporate governance aspects, which she brings to her role at Seagen. Before joining Seagen, Jean Liu gained significant experience in the biopharmaceutical sector, building a solid foundation in legal, compliance, and strategic matters. She holds a Juris Doctor (J.D.) degree, underscoring her legal expertise, and also has a Master of Science (M.S.) degree, demonstrating her dual capability in both legal and scientific domains. In her role at Seagen, she is involved in leading legal initiatives, overseeing compliance programs, and supporting corporate strategies to aid in the company’s mission to deliver breakthrough therapies to patients. Her work helps guide the company in navigating complex regulatory environments while ensuring the strategic alignment of various organizational goals. Through her leadership, Seagen continues to strengthen its position as a front-runner in cancer treatment innovation.

Mr. Charles R. Romp
Exec. VP of Commercial U.S.
No Bio Available
Dr. Roger D. Dansey M.D.
Pres of R&D

Dr. Roger D. Dansey, M.D., is a distinguished medical professional and executive in the biotechnology and pharmaceutical industry. He is currently associated with Seagen Inc., a prominent biotechnology company dedicated to developing and commercializing innovative cancer therapies. Dr. Dansey joined Seagen, Inc. in a key leadership role, where he has made significant contributions to the company's mission of advancing cancer treatment through targeted therapies. With a strong medical background, Dr. Dansey plays a crucial role in overseeing clinical development programs and guiding strategic initiatives to enhance the company's research and development capabilities. Prior to his role at Seagen, Dr. Dansey held various significant positions in the pharmaceutical industry, which showcases his extensive experience in oncology development. His career includes leadership roles at major pharmaceutical companies where he oversaw successful clinical trials and was instrumental in the development of several cancer drugs. Dr. Dansey holds an M.D. and brings a wealth of knowledge in clinical research, oncology, and drug development to his work. His leadership and expertise are vital to Seagen's efforts in providing effective and groundbreaking treatments for cancer patients.

Mr. David R. Epstein B.Sc., M.B.A.
CEO & Director

David R. Epstein is a notable executive in the biotechnology and pharmaceutical industry, currently serving as the Chief Executive Officer (CEO) of Seagen Inc., a leading biotechnology company focused on developing and commercializing innovative cancer therapies. Mr. Epstein has a wealth of experience in managing and growing biotech and pharmaceutical enterprises. Before joining Seagen, David Epstein held several significant leadership roles in the industry. He worked at Novartis, where he had a distinguished 25-year career. During his tenure at Novartis, he served as the Division Head and CEO of Novartis Pharmaceuticals, where he was instrumental in advancing the company’s strategy and expanding its product pipeline. He also played a critical role in the development and commercialization of numerous successful therapies. David Epstein holds a Bachelor of Science degree in Pharmacy from the Ernest Mario School of Pharmacy at Rutgers University. He also earned a Master of Business Administration from the Columbia University Graduate School of Business. Under his leadership, Seagen continues to be at the forefront of oncology research and drug development, making significant strides in creating treatments that improve outcomes for cancer patients. Epstein is known for his strategic vision, dedication to innovation, and commitment to enhancing patient care through scientific advancement.

Dr. Vaughn B. Himes Ph.D.
Chief Technical Officer

Dr. Vaughn B. Himes, Ph.D., is the Executive Vice President and Chief Technology Officer at Seagen Inc., a biotechnology company that specializes in the development and commercialization of innovative cancer therapies. He plays a crucial role in overseeing the company's technical operations, including process development and manufacturing, ensuring that Seagen's therapeutic products are produced efficiently and to the highest quality standards. Dr. Himes brings a wealth of experience in biopharmaceutical manufacturing and technology development to the company, having held various leadership roles in the industry. Before joining Seagen, Dr. Himes accumulated extensive experience in the field. He has previously worked with several leading biotechnology and pharmaceutical companies, which contributed significantly to his expertise in scaling up production processes for biologics. His academic background includes a Ph.D. in a relevant scientific field, equipping him with the technical knowledge and research skills essential for his role. Dr. Himes’ contributions have been integral to advancing Seagen’s mission of developing targeted therapies for cancer patients, aiming to improve treatment outcomes and quality of life. His leadership in technology operations supports the company's strategic goals and helps foster innovation in cancer treatment.

Peggy Pinkston
Sr. VP of Investor Relations
No Bio Available
Mr. David Caouette
VP of Corp. Communications

David Caouette is the Executive Vice President of Corporate Communications and Government Affairs at Seagen Inc. In his role, he is responsible for leading the company's communications strategies, including public relations, internal communications, and government affairs. Caouette's work focuses on enhancing Seagen's corporate reputation and leveraging communication channels to support the company's strategic objectives in the biotechnology and pharmaceutical industries. With a wealth of experience in communications and public affairs, he plays a crucial part in shaping and delivering key messages that align with Seagen's mission to develop therapies for cancer patients.

Mr. Matt Skelton
VP of Marketing
No Bio Available
Mr. Christopher P. Pawlowicz
Exec. VP of HR

Christopher P. Pawlowicz is an executive associated with Seagen Inc., where he serves in a leadership capacity. With a robust background in biotechnology and pharmaceuticals, Mr. Pawlowicz has been integral in steering operational and strategic initiatives at Seagen, a company renowned for its focus on developing targeted therapies to treat cancer. Leveraging extensive experience in the industry, he plays a crucial role in driving the organization's mission to advance breakthrough therapies that improve patient outcomes. His contributions encompass overseeing core business functions and fostering innovation in scientific endeavors.

Contacts

Address
WASHINGTON
Bothell
21823 30Th Drive Se, Suite
Contacts
+14255274000.0
www.seagen.com